Share 'Summit Therapeutics Shares Interim 24-Week Data from PhaseOut DMD Clinical Trial'
Today, Summit announced positive 24-week interim data from PhaseOut DMD, their Phase 2 clinical trial of the utrophin modulator ezutromid. These data showed a significant reduction in muscle damage and an increase in utrophin in muscle biopsies. Summit will host a community webinar in the coming weeks.
Read Summit's Press Release:
EZUTROMID SIGNIFICANTLY REDUCED MUSCLE DAMAGE IN DMD PATIENTS I…
You can share this blog post in two ways…
Share this link:
Send it with your computer's email program: Email this